ライフサイエンスコーパス: regimen

1 hs (month regimen) or 1, 8, and 30 days (day regimen).

2 2 cycles combined with the same obinutuzumab regimen).

3 d at month 7 (month regimen) and day 37 (day regimen).

4 ble for NTE to a conventionally fractionated regimen.

5 e outcomes by CMV risk and immunosuppressive regimen.

6 quently reported events for the chemotherapy regimen.

7 xel-capecitabine with an anthracycline-based regimen.

8 e isolates of DENV in the pre-treatment only regimen.

9 improvement in OS against an active control regimen.

10 s a component of the prophylactic antiemetic regimen.

11 on, income, smoking status, and baseline ART regimen.

12 esponse from a well-tolerated, simple-to-use regimen.

13 ccording to a T&E (n = 163) or PRN (n = 101) regimen.

14 t higher immune responses than the trivalent regimen.

15 able benefit versus risk ratio than an NSAID regimen.

16 ould not receive a more intense conditioning regimen.

17 l as simplification of the medication dosing regimen.

18 onnucleoside reverse transcriptase inhibitor regimen.

19 n effective and acceptable GvHD prophylactic regimen.

20 ing a novel, fluoroquinolone (FQ)-containing regimen.

21 s and a clinically applicable drug treatment regimen.

22 nferiority of the 3-day regimen to the 5-day regimen.

23 d by 5-9 percentage points in Bangkok across regimens.

24 ranscriptase inhibitors (NNRTIs) (32%) based regimens.

25 help formulate novel combination therapeutic regimens.

26 le checkpoints and is being studied in HNSCC regimens.

27 ents received reduced intensity conditioning regimens.

28 rapy survival after progression on frontline regimens.

29 ovide clues for developing novel therapeutic regimens.

30 me-limited bendamustine and venetoclax-based regimens.

31 to dismal patient adherence to lifelong drug regimens.

32 ents were allocated to one of these 2 active regimens.

33 irst- and second-line tuberculosis treatment regimens.

34 icine in the selection of specific treatment regimens.

35 ons coinciding with changes in the treatment regimens.

36 ations, for treatment failure of InSTI-based regimens.

37 responses were higher following heterologous regimens.

38 and those treated with both PEG/RBV and DAA regimens.

39 for high-risk patient groups and less robust regimens.

40 os (ORs) from longitudinal analyses compared regimens.

41 timal shorter therapeutic durations with new regimens.

42 s when designing immunotherapeutic treatment regimens.

43 people with DTG AEs switching to NNRTI-based regimens.

44 r drug assays employing cyclic drug exposure regimens.

45 er in Modified Vaccinia Ankara (MVA)-boosted regimens.

46 g age-appropriate WHO-recommended first-line regimens.

47 ficacy and effectiveness of different dosing regimens.

48 g cancers to current chemo- and radiotherapy regimens.

49 4% [391/465] P < 0.001, P for interaction by regimen 0.49).

50 immunogenic effect of 4 different medication regimens: (1) conventional immunomodulators (ie, oral pr

51 therapy vs placebo or an outdated antiviral regimen, 48 other treatment studies, and 33 cohort studi

52 s for the development of effective treatment regimens across PLK1-overexpressing and CIN-positive can

53 ording to the same reading center-guided T&E regimen after 3 initial monthly injections.

54 afe as an international standard 15-fraction regimen after primary surgery for early breast cancer.

55 calized or metastatic ccRCC in a microdosing regimen, after the administration of a 50-mug total of C

56 comes, assuming different preventive therapy regimens, ages, and TST positivity prevalence.

57 an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants completed the study, with n

58 is among different pharmacologic prophylaxis regimens, although our analysis is limited by small samp

59 y virus (HIV) preexposure prophylaxis (PrEP) regimens among high-risk populations, including men who

60 Five patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen devel

61 significant association between neoadjuvant regimen and any secondary outcome.

62 Pre-planned subgroup analyses included regimen and risk group.

63 /- 12% compared with 18 +/- 5% for all other regimen and transplantations (P = .003).

64 We examined the impact of initial cART regimen and weight on incident DM in a large North Ameri

65 roviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs.

66 s effects of combinatorial immunosuppression regimens and allograft failure cause significant morbidi

67 a combination therapy of current antiglioma regimens and autophagic mediators or suppressors can all

68 ity and plasticity for different therapeutic regimens and found that co-targeting of epithelial and m

69 We then tested two injection regimens and found that local beta-NGF injections during

70 r, despite the use of high-risk chemotherapy regimens and frequent HSCT upon first remission.

71 We aimed to describe the immunosuppressive regimens and graft rejection rates in living-related HLA

72 ssessed in a hierarchic model to compare the regimens and pick the winner.

73 s highly protective (85%-96% efficacy across regimens and sites) for fully covered acts.

74 o use Env trimers in multivalent vaccination regimens and the immunogenicity of trimers derived from

75 ts could be minimised by using non-isoniazid regimens and, in adults older than 18 years, focusing tr

76 Responses peaked at month 7 (month regimen) and day 37 (day regimen).

77 higher PfSPZ doses, a novel multi-dose prime regimen, and a delayed vaccine boost upon vaccine effica

78 st Indian patients taking a thrice-weekly TB regimen, and low rifampicin and pyrazinamide concentrati

79 ing the eligibility criteria for the shorter regimen, and proportional inpatient/outpatient costs fro

80 optimized with an aggressive pharmacological regimen, and regular echocardiograms were performed at r

81 if ART initiators are started on a DTG-based regimen, and those on NNRTI-based regimens are rapidly s

82 of integrase inhibitor-containing first-line regimens, and portends high rates of first-line failure

83 TB epidemic has been limited by lengthy drug regimens, antibiotic resistance, and lack of a robustly

84 on studies to enhance durability of the dual regimen are warranted.

85 Two multicomponent prime-and-boost vaccine regimens are being evaluated, one of which is designed f

86 Data comparing neurosyphilis treatment regimens are limited.

87 Improved drug regimens are needed to accelerate elimination of lymphat

88 nvasive procedures and optimize surveillance regimens are needed.Objectives: To develop and validate

89 DTG-based regimen, and those on NNRTI-based regimens are rapidly switched to DTG.

90 r control in SLE patients, immunosuppressive regimens are used, which can increase susceptibility to

91 Various antibiotic regimens are utilized nationwide with no clear guideline

92 logous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardles

93 ) to avoid misclassifying inferior treatment regimens as noninferior.

94 ug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the conventional 18-24 month reg

95 f bNAbs at 30 h, or a 21-day triple-drug ART regimen at 48 h, are aviremic with almost no virus in ti

96 t and same-day ART with a dolutegravir-based regimen at first clinic visit.

97 h the peak responses after the RV144 priming regimen at month 6; however, boosting at month 15 (group

98 taining virologic suppression vs a TAF-based regimen at week 48, with no virologic failure or emergen

99 nd low/medium dose statins (all other statin regimens) at the time of the procedure, respectively.

100 risk for standard myeloablative preparative regimens based on age (>=50 years), an HSCT-specific com

101 Our results suggest that differentiation regimens, both in the MM6 cell line and of peripheral bl

102 r patients treated with the same therapeutic regimen but who achieved different treatment outcomes.

103 t components of prostate cancer chemotherapy regimens, but their oral administration is hampered by v

104 lung cancer who were prescribed cancer drug regimens by 1,867 participating oncologists between 2013

105 ail techniques whereby promising combination regimens can be identified and further evaluated preclin

106 mely difficult because available therapeutic regimen cannot effectively kill and eliminate ERPC cells

107 citabine) or the most active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

108 rted adherence rates, preventing unnecessary regimen changes.

109 h sensitivity analysis for other setting and regimen characteristics.

110 dard group) or the same standard neoadjuvant regimen combined with HAPa immunotherapy (experimental g

111 Survival after a regimen combining rituximab with continuous-infusion che

112 We investigated two SIV vaccine regimens combining mucosal priming immunizations and sys

113 mited, PFS, with toxicity of the combination regimen comparable to prior reports.

114 effects of a 4 months preseasonal treatment regimen comprising two or three courses in consecutive y

115 The regimen consisted of two nucleoside reverse transcriptas

116 Despite many anticancer treatment regimens consisting of a cocktail of different drugs, ex

117 Although antiretroviral regimens containing integrase inhibitors rapidly suppres

118 ally resistant substitutions was higher with regimens containing lower presatovir dose and shorter tr

119 Collaboration who initiated their first ART regimen, containing either InSTI (i.e., raltegravir, dol

120 oop VNS paired with a tactile rehabilitation regimen could improve recovery of somatosensory function

121 t responses and guide personalized treatment regimens could reduce mortality.

122 to WHO-recommended dolutegravir (DTG)-based regimens could reduce this threat due to DTG's high gene

123 h CsA CE patients remained on their original regimen (CsA CE 4 times daily [QID, high-dose] or CsA CE

124 22.3%) with lower rates of VTE for identical regimens (CTD, 13.2% vs 16.1%; CTDa, 10.7% vs 16.0%).

125 All RUX regimens demonstrated therapeutic benefit at week 4; 1.5

126 k regimen and 2 patients (1%) in the 20-week regimen developed culture-confirmed recurrent melioidosi

127 revealed that the sonoselective low-pressure regimen does not up-regulate inflammatory or immune resp

128 The ACNS0333 regimen dramatically improved survival compared with his

129 the pivot drug in all tuberculosis treatment regimens due to its particular action on the persistent

130 mportant insights for selecting fractionated regimens during radiotherapy and for developing strategi

131 rate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenof

132 The vaccine regimens, especially the mucosal primes, significantly a

133 We conclude that the DFD regimen favors persistence of functional B cells after t

134 erapy with either the VRd regimen or the KRd regimen for 36 weeks.

135 mg twice daily) or placebo to their failing regimen for 8 days, followed by open-label fostemsavir p

136 osis has complicated the choice of treatment regimen for latent tuberculosis infection.Objectives: To

137 iline (BDQ) and Delamanid (DLM) in treatment regimen for patients with drug-resistant tuberculosis (D

138 carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myelo

139 HO) recommended a modified 6-month treatment regimen for people with isoniazid-resistant, rifampicin-

140 cisions in Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment."

141 to either a control or to a twice-daily LIV regimen for up to sixty cell passages (P60) under in vit

142 ied by number of previous systemic treatment regimens for advanced disease to oral ivosidenib 500 mg

143 herapy, and had up to two previous treatment regimens for advanced disease, an Eastern Cooperative On

144 Optimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent

145 e selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted t

146 ducing risk of colectomy, (6) optimal dosing regimens for intravenous corticosteroids and infliximab

147 y of new treatment options, initial systemic regimens for solid tumors are dominated by a set of stan

148 lable studies reporting modification of drug regimens for specific infections.

149 e major component of perioperative analgesic regimens for surgery in general, a variety of evidence p

150 ate use of the drug and in the design of new regimens for the treatment of RA.

151 olism randomly assigned to 1 of 4 tPA dosing regimens for ultrasound-facilitated, catheter-directed f

152 A (tissue-type plasminogen activator) dosing regimens for ultrasound-facilitated, catheter-directed f

153 (as compared to the conventional 18-24 month regimen) for patients without extrapulmonary TB, pregnan

154 A proactive treatment regimen, given in response to signal within the niche bu

155 More related AEs were reported in the day regimen group than the month regimen group.

156 ere particularly robust in the 200-mug month regimen group.

157 rted in the day regimen group than the month regimen group.

158 Compared to protein-boosted regimens, half-lives of gp120-specific antibodies were l

159 or durability of response as long as the new regimen has a cumulative activity of >2 active drugs.

160 If not available, multiple immunosuppressive regimens have been used with poor disease-free survival

161 reviewed clinical presentation, chemotherapy regimens, hematologic response, and renal and patient ou

162 d with up to eight courses of the hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine

163 mpared with historical controls treated with regimen I.

164 LVAC-SIV/CD40L was superior to the ALVAC-SIV regimen in inducing binding and tier 1 neutralizing anti

165 ntending pregnancy, and a dolutegravir-based regimen in others, and a dolutegravir-based regimen, inc

166 Here, we tested a vaccine regimen in pigtail macaques using an intranasal (i.n.) r

167 s potential to become a standard preparative regimen in this population.

168 RT initiation policies of an efavirenz-based regimen in women intending pregnancy, and a dolutegravir

169 er cancer types and to personalize analgesic regimens in patients with cancer for optimal outcomes.

170 demonstrates the ability of 3-drug induction regimens in patients with newly diagnosed multiple myelo

171 (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) were categorized according

172 routine use of weekly paclitaxel-containing regimens in the management of newly diagnosed ovarian ca

173 l data for various BRAF plus MEK combination regimens in three cancer types with underlying BRAF driv

174 nder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiv

175 to the use of reduced-intensity conditioning regimens, in parallel with more aggressive immunosuppres

176 The 5-day regimen included hygiene education, twice-daily intranas

177 treatment outcomes of this cohort show that regimens including concomitant bedaquiline and delamanid

178 regimen in others, and a dolutegravir-based regimen, including in women intending pregnancy.

179 o and ex vivo methods to show that treatment regimens, including IMiDs in multiple myeloma (MM), lead

180 The shortened group 3 regimen induced comparable peak immune responses in 30 r

181 The two-dose 5-mug adjuvanted regimen induced geometric mean anti-spike IgG (63,160 EL

182 s in the lung revealed that the airway prime regimen induced more antigen-specific multifunctional CD

183 26,MVA or MVA,Ad26) and homologous Ad26,Ad26 regimens induced humoral and cellular immune responses 2

184 Patients received a conditioning regimen, infusion of donor hematopoietic cells, then imm

185 the first time, a long-acting antiretroviral regimen injected once every 4 weeks for treatment or eve

186 eraction between MRD status and conditioning regimen intensity for relapse or survival.

187 ft rejection in recipients treated with this regimen is associated with a breakthrough of B cells and

188 The preferred treatment regimen is fidaxomicin for nonsevere CDI, vancomycin for

189 or HIV, preexposure prophylaxis with an oral regimen is recommended or, pending approval by regulator

190 The use of pediatric regimens is likely to lead to more adult patients receiv

191 t inhibitors, either alone or in combination regimens, is warranted.

192 demonstrated that the brolucizumab q12-week regimen maintains efficacy and safety while reducing tre

193 ndings suggest that optimizing the treatment regimen may extend the window of opportunity for prevent

194 ation of promising single versus combination regimens may be studied in relevant mouse models of cuta

195 t patients who progress on gemcitabine-based regimens may benefit from multidrug immunotherapy.See re

196 Short-course regimens may improve adherence.

197 Sofosbuvir (SOF)-based regimens may not be optimal among patients requiring hem

198 Discordant metabolite effects between HT regimens may partially mediate the differences in CHD ri

199 Treatment regimen (melphalan vs. combined melphalan plus topotecan

200 bsence of drug resistance to the current ART regimen.METHODSSamples were collected from at least 2 ti

201 imen (PEG/RBV, n = 4764) or a DAA-containing regimen (n = 21 279), after excluding those with diabete

202 lled and randomly assigned to either the VRd regimen (n=542) or the KRd regimen (n=545).

203 to either the VRd regimen (n=542) or the KRd regimen (n=545).

204 e of study drug (DTG/3TC, N = 369; TAF-based regimen, N = 372).

205 onclusion, the currently recommended aspirin regimen of 75 to 100 once daily for cardiovascular proph

206 A 2-dose regimen of 80 and 20 mg/kg separated by a week, resulted

207 culture results after completing a standard regimen of antituberculous treatment (ATT), with some pa

208 A two-dose regimen of BNT162b2 conferred 95% protection against Cov

209 m onset, in a 1:1 ratio, to receive a 30-day regimen of either ticagrelor (180-mg loading dose follow

210 s, followed by early initiation of an 8-week regimen of glecaprevir and pibrentasvir.

211 ograft rejection and developed a therapeutic regimen of low-dose recombinant human interleukin-2 (IL-

212 uring the second week of a 5-week outpatient regimen of motivational enhancement therapy.

213 The combination regimen of nivolumab plus ipilimumab demonstrates activi

214 Moreover, although a 12-week regimen of once-weekly isoniazid and rifapentine (3HP) i

215 the VE of different delayed fractional dose regimens of adult and pediatric RTS,S/AS01 formulations.

216 the cancer patient susceptible to subsequent regimens of drug therapy.

217 ial to identify potentially effective dosing regimens of hydroxychloroquine.

218 The regimens of interest were regular treatment interval coh

219 nto the effectiveness and costs of different regimens of IPTp-DP in settings with different underlyin

220 obulin should be included in the preparative regimens of patients with haematological malignancies se

221 critically ill patients receiving different regimens of prophylactic anticoagulation.

222 udy in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 101

223 three study groups (1:1:1) testing different regimens of trivalent Ad26.Mos.HIV (5 x 10(10) viral par

224 ates direct effects of a mucosal SIV vaccine regimen on the rectal microbiome and validates our previ

225 ouracil 2400 mg/m(2) repeated every 2 weeks (regimen one), or oxaliplatin 130 mg/m(2) administered in

226 ve the boost dose of their assigned two-dose regimen, one participant received the incorrect vaccine,

227 nd the approach lays a foundation for future regimen optimisation for patient and societal benefits.

228 eceive induction therapy with either the VRd regimen or the KRd regimen for 36 weeks.

229 d-type cutaneous melanoma, while those three regimens or combination BRAF/MEK inhibitor therapy with

230 mug) or placebo at 0, 1, and 6 months (month regimen) or 1, 8, and 30 days (day regimen).

231 ificantly with a known outpatient medication regimen (P = 0.006) and correct admission reconciliation

232 Dosage and regimen parameters correlated directly with resulting fl

233 ed with a pegylated interferon and ribavirin regimen (PEG/RBV, n = 4764) or a DAA-containing regimen

234 ssociated with an increase in evidence-based regimen prescribing from 57.1% of patients in the preint

235 l (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5).

236 (AR) is common and optimal immunosuppressive regimens remain unclear.

237 slet grafts with a short course of rapamycin regimen resulted in sustained graft survival and functio

238 assigned to the twice-daily and thrice-daily regimens showed substantially reduced interindividual va

239 rofile patient survival with respect to drug regimens, showing a significant protective effect of RAA

240 ents treated with the treosulfan-fludarabine regimen suggest its potential to become a standard prepa

241 he general preference for carbapenem-sparing regimens, suggests using ceftazidime or piperacillin-taz

242 Although currently used GVHD treatment regimens target the donor immune system, we explored her

243 tile platform for a local immune suppression regimen that can be applied to allogeneic cell transplan

244 oved using the proposed adversarial training regimen that effectively enforced local spine a priori k

245 AZI (1-g single dose) is used in an approved regimen that includes an additional antimicrobial agent

246 Continuing ART with a regimen that includes enfuvirtide post-alloBMT was safe,

247 Methionine restriction, a dietary regimen that protects against metabolic diseases and agi

248 ukaemia have poor outcomes when treated with regimens that do not contain a tyrosine-kinase inhibitor

249 s associated with resistance to chemotherapy regimens that include 5-FU.

250 approaches for drug development or treatment regimens that may affect both acute and long-term effect

251 ,000 international units once daily) or high regimen thromboprophylaxis (i.e. subcutaneous enoxaparin

252 se toward two different anthracycline-taxane regimens; thus, highlighting the prospective for precisi

253 ASA) have been proposed as a host modulation regimen to control chronic inflammatory diseases.

254 ed culture media and a mechanical stretching regimen to produce hiPSC-derived TEVGs with mechanical b

255 he criterion for noninferiority of the 3-day regimen to the 5-day regimen.

256 inetic modeling predicts that most high dose regimens trialled in COVID-19 are unlikely to cause seri

257 e daily on days 1-14 repeated every 3 weeks (regimen two).

258 orts to improve upon the prime-boost vaccine regimen used in RV144 have indicated that booster immuni

259 Treatment regimens used were: Sofosbuvir (SOF)/ribavirin (RBV)/peg

260 treated in either a prevention or treatment regimen using a commercially available beta-hydroxybutyr

261 d renal disease, death) was compared between regimens using Poisson regression.

262 Here, we evaluated CVac regimens using primaquine and/or chloroquine as the part

263 The RV305 HIV-1 vaccine regimen was a follow-up boost of RV144 vaccine recipient

264 A rifampicin-only regimen was associated with the fewest additional severe

265 IS regimen was based on either Tac or CsA in 243 (56.3%) an

266 Case fatality rate by antimicrobial regimen was calculated.

267 The tetravalent vaccine regimen was generally safe, well-tolerated, and found to

268 kalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.

269 e that the V2-specific Ab response from this regimen was highly durable and functionally diverse for

270 Susceptibility to at least 1 second-line regimen was preserved in 59%, as were susceptibility to

271 nalysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adve

272 Susceptibility to a second-line regimen was significantly higher among women, younger in

273 The median number of previous anticancer regimens was three (IQR 2-4).

274 ssion, obtained with different anticoagulant regimens, was associated with reduced mortality.

275 RMs on a morphine (or saline control) regimen were infected with SIVmac251.

276 The HT regimens were as follows: trabectedin in HG-MLPS; gemcit

277 inical outcomes remains unavailable, but DAA regimens were associated with SVR rates greater than 5%

278 tely 40% of patients in both exercise dosing regimens were classified as VO(2)peak responders (ie, De

279 Specific procedure parameters and treatment regimens were compared between the group of eyes with an

280 Three different treatment regimens were evaluated, namely pre-treatment (only), po

281 Both regimens were generally well tolerated without unexpecte

282 The most common ART regimens were nucleoside/nucleotide reverse-transcriptas

283 tatic CRC previously treated with one or two regimens were randomly assigned to irinotecan and cetuxi

284 R], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens were similar.

285 opical prednisolone phosphate; n = 57); both regimens were tapered over 10 weeks.

286 hemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable

287 efited from a reduced-intensity conditioning regimen with lower melphalan doses (FM100), which was as

288 ticipants did not complete the two-injection regimen with mosquito feeding at day 42, but were includ

289 e as efficacious as aflibercept in a q8-week regimen with regard to best-corrected visual acuity (BCV

290 Modifications of this regimen with the addition of novel monoclonal and bispec

291 ngoing surge in trials using preconditioning regimens with immunotherapy.

292 Therefore, novel PRRT regimens with improved therapeutic activity are needed.

293 receiving older antiretroviral therapy (ART) regimens with infrequent virologic monitoring.

294 Initiating first cART regimens with INSTIs or PIs vs. NNRTIs may confer greate

295 of in-vitro networks by introducing training regimens with respect to stages of neural development.

296 revious treatment with one to three systemic regimens (with at least one anti-CD20 therapy), were not

297 r drugs (including integrase inhibitor-based regimens), with fat gain due to restoration to health in

298 or ESKD to a high-dose or a low-dose IV iron regimen, with a primary composite outcome of all-cause d

299 ntibiotic treatment often follows fixed-dose regimens, with a standard dose of antibiotic administere

300 cycles of paclitaxel without dose delay, the regimen would be considered feasible.